

Tony Fiorino, M.D., Ph.D.

Biopharmaceutical executive, entrepreneur and investor with public and private company CEO experience, deep knowledge of clinical development, sound understanding of regulatory affairs and manufacturing of biologics and cell therapies, extensive experience with financial modeling and analysis, biotechnology finance and portfolio management.

- Currently CEO of BrainStorm Cell Therapeutics, a public (BCLI) biotechnology company developing a mesenchymal stem cell-based therapy for neurodegenerative diseases, where I lead clinical development, regulatory, and finance functions; raised \$25 million from institutional healthcare investors and uplisted to NASDAQ.
- Founded EnzymeRx, a start-up biotechnology company, led series A financing and acquired pegylated uricase and advanced it through two IND filings and completion of two clinical trials before selling the program to 3SBio in 2010.
- Oversaw randomized, double-blind placebo-controlled phase 2 trial of a cell therapy in ALS and served as study director and medical monitor on two phase 1/2 clinical trials in gout.
- Executed multiple regulatory functions: preparing FDA briefing documents, INDs, Fast Track and Orphan Drug filings and multiple clinical trial protocols and Investigator Brochures; led pre-IND and type C meetings with FDA.
- Successfully managed \$30-\$150 million long-short portfolios of biotechnology and pharmaceutical stocks.
- Extensive experience analyzing preclinical and clinical data, study designs, regulatory strategies, market research and prescription data across all commercially important therapeutic classes, and financial statements and data.

EDUCATION AND CLINICAL TRAINING

University of Pennsylvania Health System, Philadelphia, PA

- Intern/Resident, Departments of Medicine and Dermatology.

Medical Scientist Training Program, Albert Einstein College of Medicine, Bronx, NY

- M.D.-Ph.D. in Molecular Pharmacology; elected to *Alpha Omega Alpha*.
- Thesis research on differentiation of liver progenitor cells.

Massachusetts Institute of Technology, Cambridge, MA

- B.S. in Biology with Concentration in Cognitive Science; elected to *Phi Beta Kappa* and *Sigma Xi*.

EXPERIENCE

BrainStorm Cell Therapeutics, Hackensack, NJ and Petach Tikvah, Israel 2014-present
Chief Executive Officer and Clinical Advisor

- **Leading a publicly traded cell therapy company (BCLI) into US clinical trial and US operations.**
- Raised \$25 million and uplisted to NASDAQ in 7 months, instituted quarterly earnings calls, presented at broker and industry conferences and led multiple non-deal road shows.
- Running a phase 2 clinical development program in ALS while preparing additional clinical and preclinical neurology indications, including progressive multiple sclerosis, stroke and spinal cord injury.
- Responsible for protocol development, regulatory strategy and for overseeing manufacturing scale-up and optimization for an autologous, mesenchymal stem cell-based therapeutic.
- Managed a team of 17 employees and numerous consultants at sites in the US and Israel.

Greywall Asset Management, New York, NY 2013-2014
Managing Director

- **Helped launch a \$50 million long-short healthcare equity fund** and responsible for biotechnology investments.
- Performed in-depth analysis of preclinical and clinical data, study designs, regulatory strategies, and end-markets.

Alchimia Partners, Teaneck, NJ 2010-2014
President and Managing Member

- **Consulting practice with expertise in drug development, pharmaceutical markets, and biotechnology finance.**
- Analyze clinical and preclinical data, commercial markets and valuation for venture capital funds and hedge funds in order to provide investment recommendations.

- Provide due diligence, operational assistance and partnering/financing advice to biopharmaceutical companies.
- Invited speaker at FDA and other venues discussing drug development in the biotechnology industry.

EnzymeRx, Paramus, NJ

2008-2010

President and Chief Executive Officer

- **Founded this start-up biotechnology company and acquired pegylated uricase, in development for gout and tumor lysis syndrome.**
- Directly managed or was intimately involved in all company functions and operations, and led cross-disciplinary team of six employees, additional consultants, and multiple non-clinical, clinical and manufacturing vendors.
- Wrote multiple phase 1 and 2 clinical trial protocols, IB and IND annual reports; had lead role in all FDA meetings including pre-IND, type C and a preclinical toxicity review meeting, and successfully wrote and filed two INDs.
- Study director for two clinical trials enrolling nearly 50 gout patients in single and multiple dose designs.
- Oversaw tech transfer and scale-up of *E. coli*-based manufacturing process and directed preclinical studies, assay development and GLP toxicology studies.
- Sold the uricase program to 3SBio in late 2010.

Pequot Capital, New York NY

2005-2008

Portfolio Manager and Senior Vice President

- **Invested mainly in publicly traded biotechnology and pharmaceutical stocks and derivatives with low net exposure (0%-40%) and targeted gross exposure of 125%-200%.**
- Highly focused on emerging events involving clinical data, regulatory decisions and product launches.
- Performed in-depth analysis of preclinical and clinical data, study designs, regulatory strategies, and end-markets.

Sands Point Partners, New York NY

2003-2005

Senior Analyst

- **Managed long and short equity positions in biotechnology and pharmaceutical stocks and derivatives** focused on emerging events involving clinical data, regulatory decisions and product launches.
- Performed in-depth analysis of preclinical and clinical data, study designs, regulatory strategies, and end-markets.

Citigroup Asset Management, Stamford, CT

2001-2003

Vice President

- **Focused on biotechnology and pharmaceutical investments, industry trends, clinical data and financial modeling for multiple mutual funds and other investment portfolios.**
- Performed detailed fundamental and financial analyses using the firm's proprietary dividend discount model.
- Selected biotechnology stock holdings in Smith Barney Biotechnology and Global Healthcare mutual funds.

JP Morgan Securities, New York, NY

1998-2001

Vice President

- **Member of a highly-ranked U.S. pharmaceuticals equity research team.**
- Focused on pharmaceutical industry trends, analysis of prescription data, pipeline analysis, and financial modeling.
- Extensive analysis of new product launches, and legal, patent and regulatory issues in the generics industry, wrote company and industry reports and built financial and market models.

OTHER

- Published medical and scientific papers in journals including the *Journal of Clinical Oncology*, *Annals of Internal Medicine*, *In Vitro*, *Leukemia*, *Brain Research Reviews* and *Obstetrics & Gynecology*, and presented posters at ACR and ASH.
- Served on Boards of Stemline and several not-for-profit institutions.

CONTACT

afiorino@alchimiapartners.com

www.alchimiapartners.com

www.linkedin.com/in/afiorino